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Abstract
ROLE OF ROCK AND PKC IN REGULATION OF CONTRACTION OF
PERMEABILIZED FEMORAL ARTERIAL SMOOTH MUSCLE
by Brendan M. Browne, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Director: Paul H. Ratz, Ph.D.
Professor, Department of Biochemistry and Pediatrics

KCl is traditionally used as a stimulus to examine the role of increases in cytosolic Ca 2+
on the regulation of smooth muscle contraction. KCl bypasses GPCR activation, thereby
avoiding activation of additional cell signaling systems, such as phospholipase C and
PKC that are inherent to Gαq and Gα12/13 stimulation. GPCR activation causes Ca2+
sensitization (greater force for a given increase in Ca2+) by a ROCK- and PKC-dependent
inhibition of myosin light chain (MLC) phosphatase. Recent studies have demonstrated
that KCl can also produce Ca2+ sensitization, implying that Ca2+ itself may induce Ca2+
sensitization. To test the hypothesis that Ca2+ can induce Ca2+ sensitization, we
permeabilized rabbit femoral artery rings with β-escin and subjected the tissues to a Ca2+
concentration response curve in the absence (control) and presence of selective inhibitors
of ROCK and PKC, the general ser/thr kinase inhibitor, staurosporine, and the MLCK
inhibitor, wortmannin. For a comparison, tissues permeabilized with β-escin were also
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contracted with the α-adrenergic agonist, phenylephrine (PE), and exposed to the same
complement of inhibitors. Interestingly, Ca2+-induced contraction was inhibited by a PKC
inhibitor in β-escin-permeabilized tissue. Wortmannin and staurosporine nearly abolished
Ca2+-induced contraction. The ROCK inhibitor, H-1152, significantly reduced Ca2+- and
PE-induced contractions in β-escin permeabilized tissues.

Western blots showed

significant decreases in basal MYPT1-pThr853 by ROCK inhibitors and reduction of
MLC-p by ROCK and PKC inhibitors. These data support our hypothesis that elevations
in Ca2+ or constitutive ROCK activity may cause ROCK-dependent Ca2+ sensitization.
Moreover, data also suggest the possibility of PKC-directed activation of the
RhoA/ROCK cascade. Once the mechanism for smooth muscle Ca2+ sensitization is
understood, advanced treatments for vascular hyper-contraction disorders, such as
vasospasm and hypertension, may be possible.

ix

INTRODUCTION
1.1 Basic smooth muscle physiology
Vertebrate muscle contracts due to actin-myosin cross bridge cycling, in which
thick and thin muscle filaments slide across one another, shortening the muscle cell and
generating force. A transient increase of intracellular calcium ([Ca2+]i) serves as the
cellular signal to produce appreciable levels of tension via actomyosin hydrolysis of
adenosine triphosphate (ATP). All muscle types – skeletal, cardiac and smooth – employ
similar contractile processes, but there are numerous structural and functional
components specific to smooth muscle.
Smooth muscle is uni-nucleated, non-striated muscle found predominantly in
hollow organs, including vasculature, respiratory airways, the urinary bladder, the
gastrointestinal tract and others.

These systems utilize smooth muscle to facilitate

motility and maintain organ dimensions against imposed forces. Smooth muscle consists
of two subtypes – phasic and tonic – based on different kinetics and force development
profiles from KCl-induced contraction. Upon activation, phasic muscle exhibits rapid
force development immediately followed by relaxation to the initial passive tension, e.g.
phasic contraction in gastrointestinal peristalsis to promote food motility. Alternately,
tonic smooth muscle demonstrates an initial phasic contraction followed by sustained
monotonic elevation of muscle tone. This persistent muscle tone is utilized throughout
the vascular system to dictate blood pressure.
A unique characteristic of smooth muscle is the absence of troponin as a
regulatory molecule. In striated muscle, the troponin-tropomyosin complex covers the
1

myosin II attachment sites on the globular actin thin filament. With sufficient increase of
[Ca2+]i, troponin-C binds Ca2+ and the complex undergoes a conformational change to
expose the binding sites for myosin II heads. Provided that ATP is present, myosin II
ATPase will bind globular actin and proceed with cross-bridge cycling to generate force.
This mechanism of regulation ensures that the cell contains sufficient energy in the form
of ATP and an appropriate Ca2+ stimulus to initiate muscle contraction. Although it is
devoid of troponin, smooth muscle exhibits thin filament regulation utilizing the proteins
calponin and caldesmon (Earley, Su et al. 1998, Gusev 2001).
Smooth muscle exhibits some degree of thin filament regulation, but the primary
means to control force development is through phosphorylation of a 20-kilodalton (kDa)
regulatory myosin light chain (MLC), a subunit of myosin II that comprises the thick
filament of the contractile apparatus. MLC phosphorylation is not necessary for striated
muscle contraction, but smooth muscle requires phosphorylation at a specific MLC
peptide to increase actomyosin ATPase activity and cross-bridge cycling to a significant
rate (Cassidy, Hoar et al. 1979). Unphosphorylated MLC abrogates ATP exchange in
myosin heads and thus precludes the development of force.
Since a dominant physiological function of smooth muscle is maintenance of
muscle tone, tonic muscle must sustain considerable tension while exhibiting
considerable energy economy. Isometric force continues to increase monotonically to a
sustained steady-state in tonic smooth muscle despite decreased MLC phosphorylation,
[Ca2+]i, cross-bridge cycling rate and ATP consumption (Kamm and Stull 1985).
Although the molecular process for persistent tonic force has been researched for nearly
2

three decades, no conclusive mechanism has yet been devised.

The current model

employs the ‘latch-bridge’ concept (Figure 1), in which dephosphorylation of the MLC of
an intact actomyosin complex results in a catch-like connection between the thick and
thin filaments, termed a latch-bridge (Dillon, Aksoy et al. 1981). Dephosphorylation of
the MLC regulatory subunit in an attached cross-bridge slows myosin II detachment
kinetics relative to the phosphorylated state (Hai and Murphy 1988; Ratz, Hai et al.
1989). Further supporting the latch-bridge hypothesis, a recent study showed that ADP is
released faster in cross-bridges with phosphorylated MLC, possibly due to a
conformational change of the myosin II head (Somlyo, Khromov et al. 2004). The rigid
latch-state resists the movement of thick and thin filaments and therefore would maintain
muscle tone while not requiring continued ATP consumption, accomplishing sufficient
energy economy. The latch-bridge hypothesis does explain the efficient maintenance of
force, but biochemical pathways appear to contribute to this phenomenon. Evidence
from our laboratory demonstrates that inhibition of RhoA kinase (ROCK) can selectively
A + Mp
pi

ATP

AMp

AM

Cross-bridge
cycling

Latch-bridge
formation

ADP

Tension

Tonic tension

Figure 1. – Schematic of latch-bridge model (modification from Hai, Murphy 1988). A latchbridge is the structure resulting from dephosphorylation of an attached cross-bridge. Latchbridges detach much slower than cross-bridges, maintaining tonic force in an energy efficient
manner. A, Actin; Mp, phosphorylated Myosin; AMp, attached Actin and phosphorylated Myosin
(cross-bridge); AM, attached Actin and unphosphorylated Myosin (latch-bridge); ATP, Adenosine
Triphosphate; ADP, Adenosine Diphosphate; Pi, phosphate
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diminish tonic force independent of changes in [Ca2+]i (Urban, Berg et al. 2003),
indicating a significant role for ROCK in smooth muscle force maintenance.

1.2 Phosphorylated Myosin Light Chain Ratio
The extent of smooth muscle contraction relies primarily on phosphorylation of
the regulatory MLC that controls contractile thick filament actomyosin ATPase activity.
To achieve MLC phosphorylation, muscle cells require ATP as a source of energy and
phosphate, and generally an increase in [Ca2+]i although Ca2+-independent contractions
can also occur. Elevated [Ca2+]i enables binding of Ca2+ to the protein calmodulin (CaM),
inducing a conformational change (Krueger et al. 1998) that facilitates complexation with
and activation of myosin light chain kinase (MLCK). MLCK is a dedicated kinase that
recognizes and binds specific amino acids – specifically Arg16, Phe22 and Val21 – in the Nterminus of MLC (Pearson et al. 1985, Zhi et al. 1994). Enzymatic phosphorylation
occurs at Ser-19 of MLC (Stull et al. 1986), altering the protein’s C-terminus to
potentiate the associated actomyosin ATPase that directs muscle contraction (Trybus and
Chatman, 1993). Recent studies with MLCK knockout mice identified other kinases that
also phosphorylate MLC, some of which are Ca2+-independent (Somlyo, Wang et al.
2004), but MLCK is still considered the predominant kinase involved in MLC
phosphorylation.
A rapid decrease in tension upon cessation of muscle activation or in the presence
of relaxing agents is accomplished by constitutive and increased activity of myosin light
chain phosphatase (MLCP), an enzyme that dephosphorylates Ser-19 of smooth muscle
4

MLC halting progressive cross-bridge cycling.

The MLCP holoenzyme exists as a

heterotrimer, requiring all components for maximum activity. The active site is the 38kDa catalytic subunit of type 1 protein phosphatase (PP1c-δ) (Alessi, MacDougal et al.
1992; Gong, Cohen et al. 1992). PP1c-δ is attached to the N-terminus of a 110-kDa
subunit responsible for regulation and specific binding, aptly named myosin phosphatase
targeting subunit 1 (MYPT1) (reviewed by Hartshorne et al. 1998; Ito et al. 2004).
Bound to the C-terminus of MYPT1 is a 20-kDa subunit (M20), for which the function
has not yet to been determined.

MLCP activity can be modulated by site-specific

phosphorylation or association with endogenous inhibitor molecules.
Because these two enzymes act in direct competition with one another, the ratio of
MLCK / MLCP activity accounts for the level of Ser-19 phosphorylation on MLC. A
high value for the MLCK / MLCP activity ratio correlates to high MLC phosphorylation.
Though Ca2+ is considered the key regulator of smooth muscle cell behavior because it
activates MLCK (Kamm and Stull, 1985), there are several Ca2+-independent
mechanisms that modulate MLCK and MLCP activity (Somlyo, Wu et al. 1999). As
pharmacomechanical coupling of smooth muscle contraction is further elucidated,
specific regulation of MLCK and MLCP will allow scientists and physicians to
accurately control the activity ratio and consequently the contractility of physiological
hollow organ systems containing smooth muscle.

5

1.3 Calcium Regulation
Calcium is one of the most important intracellular signaling molecules, acting as a second
messenger for a plethora of cellular activities (Campbell AK, 1983), and has long been
known to participate in vertebrate smooth muscle contraction (Fay, Shlevin et al. 1979;
Neering and Morgan, 1980; Morgan and Morgan, 1982). Smooth muscle precisely
manipulates Ca2+ levels to keep [Ca2+]i low at rest: approximately 100nM for rabbit
femoral artery (Ratz, 2005) relative to 1.5 mM in the external medium. Because [Ca2+]i is
such an significant effector of cellular behavior, the intracellular concentration is highly
regulated by multiple ion channels and pumps, as well as storage compartments and
buffers (Figure 2). The primary determinant of [Ca2+]i is Ca2+ influx from extracellular
sources.

Calcium crosses the plasma membrane through L-type Voltage-Operated

Calcium Channels (VOCCs) or non-selective cation channels, and also enters the cytosol
from stores in the sarcoplasmic reticulum (SR).

VOCCs are opened by membrane

depolarization, which is accomplished by activating non-selective cation channels, or
inhibiting K+ or Cl- channels that are responsible for cellular resting membrane potential.
Agonists that act through G protein-coupled receptors (GPCR), e.g. α-adrenergic receptor
activation, can open VOCCs in the absence of membrane depolarization. Additionally,
Receptor-Operated Calcium Channels (ROCCs) facilitate the Ca2+ influx upon direct
agonist-induced activation of GPCR. Intracellular Ca2+ stores in smooth muscle SR are
released by Ca2+-induced Ca2+-release through Ryanodine receptors or by activation of
Ca2+-channels with inositol triphosphate (IP3) (reviewed by Karaki et al. 1997; Lee,
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Poburko et al. 2002, Wray et al. 2005). Store-Operated Calcium Channels (SOCCs) act
to refill the SR Ca2+-stores from the external medium after periods of SR Ca2+ depletion.
After the stimulus for Ca2+-influx has abated, cells must decrease [Ca2+]i to preactivation levels to ensure that subsequent stimulation achieves a comparable increase of
[Ca2+]i.

Homeostasis is recovered as the transmembrane Ca2+ pump and Na+/Ca2+

exchanger extrude Ca2+ from the cell or site-specific pumps sequester Ca2+ into the SR.
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Figure 2. – Cellular calcium regulation. Diagram showing sources of Ca2+ influx (modified from
Ratz, 2005). To decrease intracellular Ca2+, ions are pumped out of the cell or sequestered into
the SR. VOCC, Voltage Operated Calcium Channel; SOCC, Store Operated Calcium Channel;
ROCC, Receptor Operated Calcium Channel; SR, Sarcoplasmic Reticulum; IP3, inositol 1,4,5triphosphate
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1.4 Calcium Sensitization
Early smooth muscle researchers noted significantly increased stress development
in tissues contracted with a GPCR-activating stimulus versus a depolarizing (high [KCl]
solution) stimulus despite equivalent values for [Ca2+]i (Morgan and Morgan, 1984;
DeFeo and Morgan 1985; Himpens and Casteels, 1987; Himpens, Kitazawa and Somlyo,
1990; Ratz, 1999). Furthermore, addition of cyclic nucleotides can attenuate force with
no concurrent decrease in [Ca2+]i.

Ca2+-clamped (permeabilized) smooth muscle

stimulated with GPCR agonists or guanosine 5’-O-(3-thiophoasphate) (GTPγS) displayed
increased force and MLC phosphorylation (Ruegg and Pfitzer, 1985; Kitazawa T,
Kobayashi S, et al. 1989), reinforcing previous data from intact tissues. The compiled
results indicated that the cellular response of smooth muscle to Ca 2+ is variable. For a
given [Ca2+]i, complex molecular mechanisms increase or decrease contractile force and
MLC phosphorylation, termed Ca2+-senstization or Ca2+-desensitization respectively.
Since the initial description of this phenomenon, Ca2+ sensitization has proven to be
equally salient as [Ca2+]i in controlling smooth muscle contraction (reviewed by Savineu
Marthan, 1997; Somlyo and Somlyo 1998, 2003). Though Ca2+ sensitization is primarily
incurred by modulation of MLCP activity, it can also arise from differential MLCK
activity, thin filament regulation or possibly interaction of heat shock proteins with the
contractile apparatus and structures that propagate tension (Kubota, Nomura et al. 1992;
reviewed by Kamm and Stull 2001; Kawano et al. 2002).

9

1.5 GPCR role in Calcium Sensitization
Ca2+ sensitization utilizes multiple signaling pathways to inhibit MLCP activity
(review Hartshorne 1998; Somlyo 2003), thereby increasing the phosphorylated MLC
value to promote further force development at constant [Ca2+]i. A well-documented mode
of Ca2+-sensitiziation proceeds through transmembrane receptor activation of trimeric Gproteins containing Gαq or Gα12/13 subunits (reviewed by Somlyo 2003). Activation of
these Gα subunits results in downstream inhibition of MLCP (Figure 3), which is
primarily mediated by the serine/threonine kinases: protein kinase C (PKC) and RhoA
coiled-coil kinase (ROCK).

The G-proteins and much of the intermediate protein

cascade are localized to the plasma membrane, and therefore require mobile effector
molecules to enact sensitization at the intracellular contractile machinery.
Gαq is activated by a myriad of agonists, including: acetylcholine [muscarinic
M1], α-adrenergic agonists, angiotensin II, ATP [P2x and P2y], histamine [H1], plateletderived growth factor, serotonin [5-HT-1c], thyrotropin-releasing hormone and
vasopressin. Upon receptor stimulation, Gαq initiates a protein cascade via activation of
phospholipase C (PLC).

This enzyme cleaves phosphatidylinositol-4,5-bisphosphate

(PIP2) into IP3, which triggers release of SR Ca2+ stores through agonist-specific channels,
and diacylglycerol (DAG), a membrane bound molecule that activates PKC in the
presence of intracellular Ca2+.

PKC phosphorylates the 17-kDa PKC-activated

phosphatase inhibitor (CPI-17, Eto et al. 1995, 1997) at the regulatory Thr-38 residue to
potentiate the molecule’s inhibitory capacity (Kitazawa, Eto et al. 2003). Therefore Gαq
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is able to produce Ca2+ influx, SR Ca2+ release and Ca2+ sensitization simultaneously.

PLCβ

Although CPI-17 is a very potent MLCP inhibitor, its involvement in Ca2+ sensitization

α12/13

γ

αq
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Figure 3. - Schematic for GPCR-directed Ca2+ sensitization. Sensitization results from MLCP
inhibition by CPI-17 and/or ROCK. Gq activates CPI-17 and G12/13 activates ROK (ROCK).
α,β,γ, are the subunits of trimeric G protein; GTP, guanosine triphosphate; GDP, guanosine
diphosphate; GDI-RhoA-GDP, inactive RhoA GTPase; RhoA-GTP, active RhoA GTPase; ROK,
RhoA Kinase (ROCK); PLCβ, phospholipase C beta; PIP2, phosphatidylinositol di-phosphate;
IP3, inositol 1,4,5-triphosphate; DAG, diacylglycerol; PKC, protein kinase C; CPI-17, 17-kDa
PKC-activated phosphatase inhibitor

depends on the level of cellular expression. CPI-17 is present in high quantities in tonic
smooth muscle, while phasic smooth muscle exhibits substantially lower concentrations
to the point that PKC:CPI-17 mediated Ca2+ sensitization is physiologically irrelevant
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(Kitazawa, Eto et al. 2003). Moreover, CPI-17 is not expressed by avian smooth muscle
(Kitazawa, Polzin and Eto, 2004).
Agonists that bind receptors containing the Gα12/13 subunit mobilize a PLCindependent protein cascade resulting in MLCP inhibition. The pathway triggered by Gα
12/13

(Fukuhara, Chikumi and Gutkind, 2001) – and also seen in Gαq signaling (Booden,

Siderovshi and Der, 2002) – utilizes Gα-coupled Guanine Exchange Factors (GEF) that
facilitate exchange of GDP for GTP in membrane-localized small GTPases, particularly
RhoA, the upstream activator of the ROCK.

ROCK phosphorylates two threonine

residues on MYPT1 that leads to inhibition of the MLCP holoenzyme. Phosphorylation
of MYPT1 Thr-853 causes MLCP to dissociate from the phospho-myosin substrate
(Velasco, Armstrong et al. 2002) and phosphorylation of Thr-696 directly inhibits MLCP
activity (Feng, Ito et al. 1999). MYPT1 has been identified as a primary target of ROCK
(Kimura, Ito et al. 1996, Velasco et al. 2002), but recent studies have indicated that
MYPT1 is also phosphorylated by ZIP kinase (Borman, MacDonald et al 2002;
MacDonald, Borman et al. 2001) and integrin-linked kinase (ILK; Deng, Van Lierop et
al. 2001; Kiss, Muranyi et al. 2002; Niiro and Ikebe, 2001). Though Gαq and Gα12/13
commonly promote Ca2+ sensitization by a protein cascade that results in ROCK and/or
PKC activation, there are additional salient physiological pathways for effector kinase
activation and subsequent Ca2+-sensitization, including arachidonic acid and other lipid
derivatives (Feng et al. 1999).
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1.6 Plasma Membrane and Caveolae
Interactions along the plasma membrane of vertebrate smooth muscle control a
large contingent of cellular behaviors. The channels, pumps and GPCRs responsible for
[Ca2+]i are all situated at the plasma membrane, and it is hypothesized that the crucial
sensitizing enzyme ROCK may require membrane localization for activation (Ratz 2005).
The plasma membrane of smooth muscle consists of at least three domains: focal
adhesions, dystroglycan complexes and caveolae. Focal adhesions and dystroglycan
complexes connect the intracellular actin cytoskeleton to the extracellular matrix and
integrate tension from adjacent cells to generate macroscopic force. To accommodate
much of the biochemical cellular signaling, smooth muscle cells employ the 50-100 nm
cave-like invaginations called caveolae.

These structures are unique from other

membrane domains by nature of their composition of cholesterol, sphingolipids and
proteins – notably caveolin-1 (reviewed by Smart, Graf et al. 1999). Smooth muscle
sarcolemma is organized such that caveolae and dystroglycan are frequently co-localized
while there is virtually no overlap between caveolae and focal adhesions, generating an
alternating spatial organization. The caveolin family of proteins functions as scaffold
proteins for the high density of cellular signaling molecules concentrated at caveolae,
including transmembrane GPCRs, receptor Tyrosine kinases, PKCs, members of the
MAP kinase pathway and others (Sargiacomo et al. 1995). Studies demonstrate that
treatment with GPCR agonists promotes the translocation of inactive RhoA (bound to
RhoA-GDI) from the cytosol to the plasma membrane for activation (Fujihara, Walker et
al. 1997; Gong, Fujihara 1997; Taggert, Lee et al. 1999). The localized, activated RhoA13

GTP turns on ROCK to inhibit MLCP, indicating caveolae as a possible site for
regulation of Ca2+-sensitization. This hypothesis is further supported in studies using
caveolin-1 knockout and cholesterol-depleted smooth muscle, in which the potency of
GPCR-activated contraction is significantly reduced compared to KCl stimulation (Drag,
Verkade et al. 2001; Dreja, Voldstedlund et al. 2002).

1.7 Membrane depolarization with KCl and KCl-induced Ca2+ Sensitization
Due to the considerable number of agonists for Gαq- and Gα12/13-directed Ca2+
sensitization, studying the underlying mechanism for Ca2+-only contraction in smooth
muscle is very complicated.

Therefore, researchers attempt to circumvent GPCR

sensitization using, as a stimulus, concentrated KCl solution, which adjusts the K+
equilibrium potential and clamps the cell in a depolarized state. Depolarization allows
Ca2+ influx through VOCCs to increase [Ca2+]i and to direct activation of CaM:MLCK.
This technique was based on the premise that [Ca2+]i is the primary regulator of smooth
muscle contraction and was postulated to circumvent the complex sensitization
mechanisms inherent in GPCR activation (Karaki 2004). Contraction devoid of GPCRdirected sensitization has allowed detailed description of smooth muscle Ca2+
sensitization by comparative physiology.
Experimental use of KCl as an electromechanical stimulus indicated the
involvement of additional mechanisms affecting force development. KCl has proven to
nominally activate intracellular signaling pathways, modulating MLCK activity – both
positively and negatively – through activation of Ca2+/calmodulin-dependent protein
14

kinase II (CaMKII) and extracellular signal-regulated kinase (ERK). Moreover, recent
studies show that smooth muscle contracted with a concentrated KCl stimulus does show
moderate levels of Ca2+-sensitization.

Our laboratory and others have shown that

inhibition of ROCK can greatly attenuate the tonic tension produced by KCl contraction
(Kupittayanant S, Burdyga and Wray, 2001; Anabuki et al. 2000; Sakamoto, Hori et al.
2003; Sakurada, Takuwa et al, 2003; Urban, Berg and Ratz, 2003). Since KCl activates
smooth muscle contraction by adjusting cellular resting membrane potential and
consequently opening VOCCs for Ca2+ influx, depolarization and/or elevation in [Ca2+]i
may lead to ROCK activation and Ca2+ sensitization. Ca2+ Calmodulin-dependent GEFs
have been found to activate the membrane protein Ras, but no Ca2+ activated GEFs
associated with RhoA activation have yet been identified.
Studies in intact rabbit femoral artery demonstrate that KCl causes localization of
ROCK, but not RhoA, to caveolae (Urban and Ratz 2004; Urban et al. 2003). However,
considerable amounts of RhoA are constitutively present at caveolae in the active form
(the inactive form is bound to GDI in the cytosol), and thus any ROCK localized to the
plasma membrane can be activated to initiate Ca2+ sensitization. Muscle activation with
the Ca2+ channel agonist, BayK8644, has shown that ROCK recruitment to caveolae
occurs with Ca2+ influx in the absence of membrane depolarization (Urban, Berg and Ratz
2003), indicating Ca2+ as a possible stimulus for membrane localization. Direct activation
of Ca2+-sensitizing mechanisms by [Ca2+]i would suggest that Ca2+-activated contraction
and Ca2+ sensitization are one congruent system.
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1.8 Permeabilization
Chemical permeabilization is an important experimental technique that enables
researchers to dictate intracellular concentrations of salient cellular constituents. Smooth
muscle researchers frequently employ chemically permeabilized cells to examine the
effects of constant [Ca2+] on contraction (Kitazawa, Kobayashi et al. 1989). The precise
control of cytosolic composition has also allowed investigation of individual Ca2+sensitizing agonists and pathways in a variety of smooth muscle tissues (Anabuki, Hori et
al. 2000; Sward, Dreja et al. 2000; Takeuchi, Kushida et al. 2004; Durlu-Kandilci and
Brading 2006).
The four predominant permeabilizing agents utilized in smooth muscle research
are: Triton X-100, saponin, β-escin and α-toxin. The first three of these permeabilizing
agents are amphipathic detergents that effectively disrupt cellular membranes by
depleting hydrophobic phospholipids. Depending on the nature of the detergent, various
degrees of permeabilization and disruption of cellular mechanisms can be incurred.
Triton X-100 is a non-ionic surfactant that achieves vigorous permeabilization of the
sarcolemma and the SR membrane. Additionally, Triton X-100 abrogates all membraneassociated processes, uncoupling transmembrane receptors that are largely responsible for
Ca2+ sensitization (Kitazawa, Takizawa et al. 1999). Saponin is a class of amphipathic
molecules known to complex with cholesterol molecules in the plasma membrane.
Chemical permeabilization with saponin solution generates 9 nm pores in the plasma
membrane for transit of small molecules and uncouples membrane receptors involved in
pharmacomechanical coupling of smooth muscle contraction (Bangham, Horne et al.
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1962; Kitazawa, Kobayashi et al. 1989). β-escin enacts a less vigorous permeabilization
of the cellular membrane than saponin, generating pores that can pass molecules up to
150 kDa (Iizuka et al. 1994). Contrasting saponin, β-escin permeabilized tissues retain
their receptor signaling mechanisms (Kobayashi, Kitazawa et al. 1989) and show mild
inhibition of SR function, though the SR membrane remains intact (Launikonis and
Stephenson 1999). The least destructive permeabilizing agent, α-toxin, forms pores
permeable to small molecules up to 3 kDa, while maintaining SR membrane integrity and
transmembrane receptor-mediated processes (Kitazawa, Kobayashi et al. 1989).

1.9 Objective
Studies indicating that some level of Ca2+ sensitization participates in a KCl –
induced contraction undermine the previous model depicting Ca 2+ contraction and
sensitization as autonomous mechanisms. A thorough model of KCl-induced contraction
will allow studies of comparative physiology to improve the understanding of GPCRactivated contraction. KCl acts as a depolarizing stimulus, facilitating Ca2+ influx by
opening of VOCCs, indicating membrane depolarization and/or increased [Ca2+]i as an
initiator of Ca2+ sensitization through the ROCK pathway. Permeabilizing arteries with
β-escin eliminates resting membrane polarization and allows precise clamping of
effective [Ca2+]i. The objective of this project is to utilize β-escin permeabilized tissue to
examine whether Ca2+ is responsible for activation of the ROCK sensitization mechanism
in rabbit femoral arterial smooth muscle.
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MATERIALS AND METHODS
2.1 Tissue Preparation
Tissues were prepared as previously described (Ratz 2003). Female New Zealand
White rabbits were anesthetized and killed as approved by the Medical College of
Virginia at Virginia Commonwealth University Institutional Animal Care and Use
Committee protocol #0305-32081. Femoral arteries were immediately removed and kept
in cold (4oC) normal physiological saline solution (NPSS; in mM: 140 NaCl, 4.7 KCl, 2.0
morpholino-propanesulfonic acid (MOPS), 0.02 ethylenediaminetetraacetic acid (EDTA)
– to chelate heavy metals –, 1.2 Na2HPO4·7H2O, 1.2 MgCl2, 1.6 CaCl2, 5.6 α-D-glucose
and adjusted to pH 7.4 at 37oC with 5N NaOH). High purity (18.2 MΩ) deionized water
was used throughout the study. Fat and adventitia were mechanically removed under a
binocular dissecting microscope (Olympus SZX12 or Zeiss 10093) and stored in 4oC
NPSS for no more than four days. On the day of experimentation, the endothelium was
removed from all arteries by gently rubbing a roughened rod of similar diameter through
the arterial lumen. The arteries were cut into 2-3 mm rings for experimentation.

2.2 Isometric Force
Contractile force (F) was measured as previously described by Ratz (1993). Each
arterial ring was suspended on two stainless steel pins in separate 5 mL wells (Fig 4 and
5, Myograph System 610M – Danish Myo Technology, Denmark); the pins were
connected to a micrometer for tissue length adjustments and an isometric force transducer
for force measurement. Voltage signals from the Myograph were digitized and displayed
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as F in grams on a computer screen. Data were acquired through an analog-digital
converter

Figure 4. Model Myograph System-610M; diagram from owners manual. The system facilitates
precise control of temperature and tissue length while recording isometric force. Bath solutions are
changed by vacuum suction to allow rapid changing of experimental milieu.

board (National Instruments) and analyzed using DASYLab 8.0 (DasyTech, Amherst,
NH). Tissues were allowed to equilibrate at 37oC for one hour prior to a “wake-up”
contraction using potassium physiological saline solution (KPSS; NPSS with 110 mM
KCl isosmotically substituted for NaCl). For all tissues, “wake-up” was followed by an
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abbreviated length-tension curve to identify optimum contraction force (Fo) and length
(Lo) for each tissue (Herlihy and Murphy 1973; Ratz and Murphy 1987).

Figure 5. Tissue bath of Danish MyoTech 610M system; photo from owners manual. The artery
ring is suspended on two stainless steel pins, one leads to the isometric force transducer and the
other is attached to the micrometer.

2.2.1 Raw Data
All raw data were recorded as grams of force and the graphical models
approximated typical force tracings, including “wake-up” and Lo contractions in intact
tissue (Figure 6) as well as “wake-up”, pCa and PE contractions in permeabilized tissues
(Figure 7). Statistics were not compiled for raw data.
2.2.2 Standard Warm-up and Tissue “Wake-up”
After tissue wells had warmed to 37oC, the Myograph system was calibrated using
the DASYLab software to standardize force recording. Tissues rings were hung on the
Myograph pins, stretched to 0.5 g force and allowed to equilibrate in aerated NPSS for
one hour at physiological temperature (37oC). During warm-up, tissues experienced
stress relaxation, after which they were re-stretched to 0.5 g for five minutes. The NPSS
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was then substituted for KPSS for five minutes, eliciting a “wake-up” contraction, then
relaxed for 15 minutes in NPSS.
2.2.3 Lo determination
The optimal length of contraction (Lo) for experimental artery rings was
determined for individual tissues using an abbreviated length-tension curve (Herlihy and
Murphy 1973; Ratz and Murphy 1987). The value of L o was recorded as the ratio of
passive force (FP) to active force (FA = FT - FP) and, for rabbit femoral artery, was attained
within the range of 0.13 ± 0.03, as determined by previous full length tension data
(unpublished).
The abbreviated length-tension curve began by stretching the tissue in 0.5
g increments up to 2.0 g force. The micrometer was then dialed down to a calculated
passive force value and the tissue was contracted in warm KPSS for five minutes.
Decreasing the tissue length broke any potential intact latch-bridges and adjusted tissues
visco-elastically to allow accurate measurement of passive tension. The indicated dialdown value was estimated by FP = ((FT * 0.13)/1.13), where 1.13 adjusted for the
inclusion of FT rather than FA in the formula. The tissue was relaxed by washing three
times with NPSS over a period of 15 minutes. The average force of contraction measured
immediately prior to washout of KPSS was used in the subsequent abbreviated lengthtension curve. Abbreviated curves were compiled until the empirical Lo falls within the
appropriate range.
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Figure 6. – Tissue wake-up and Lo determination. Tissues are warmed to physiological
temperature (37oC) in NPSS for 45’ to 1 hour. Tissues are stretched prior to contraction for 5’ in
KPSS to reactivate the tissue. After wake-up contraction tissues are allowed to relax for 10’ then
subjected to Lo determination. Tissues are stretched at intervals of 0.5g every 5’ until they reach
2.0g. Length is rapidly decreased to reach a predetermined passive force at which point tissues are
again contracted for 5’ in KPSS. Tissues are washed twice with NPSS and allowed to relax for
10’. This process is repeated at least once more until the passive to active force ratio is 0.13±0.03.
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2.3 Tissue Permeabilization
Artery rings at Lo were washed in calcium-free “relaxing solution” (RS; in mM:
74.1 potassium methanesulfonate, 4.0 magnesium methanesulfonate, 4.0 Na2ATP, 4.0
EGTA, 5.0 creatine phosphate, 30.0 PIPES, adjusted to pH 7.1 with 1N KOH and ionic
strength 0.18 with additional 0.5M potassium methanesulfonate). All tissues were then
chemically permeabilized with 100 µM β-escin for 45 minutes at 4oC then 15 minutes at
30oC. The initial treatment with β-escin at low temperature facilitated slow penetration
and/or binding of β-escin to the surface of the smooth muscle membrane (Masuo,
Reardon et al. 1994). Artery rings were washed thoroughly with RS then incubated for
20 minutes at 30oC in RS containing 10 µM A23187, a Ca2+ ionophore that depleted SR
Ca2+.
To reactivate permeabilized tissues, each underwent an internal control
contraction where [Ca2+] was clamped at pCa 6.0 (1 µM CaCl2) in “contracting solution”,
which was made by adding 1 M CaCl2 stock (Fluka Chemicals) to RS in appropriate
amounts as determined by WEBMAXC (Patton, Thompson et al. 2004). The tissues
were contracted for 10 minutes and then allowed to relax in RS with 10 µM A23187.
The peak of this internal control contraction was used to normalize data recorded during
experimental treatment.

2.4 Calcium Concentration Response Curve
Permeabilized tissues underwent an internal control contraction and relaxation at
30oC followed by 15-minute incubation in the presence of specific kinase inhibitors. A
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force-pCa concentration response curve (CRC) was constructed using eleven solutions of
different [Ca2+], increasing incrementally from 3.16 x10-8 (pCa = 7.5) to 10-5 (pCa = 5).
Contractile force was allowed to plateau before the solution was exchanged for the
subsequent Ca2+ concentration. Artery rings were then relaxed in calcium-free RS. Raw
data were collected and normalized before statistics were run.

2.5 PE Sensitization Experiment – Permeabilized Tissue
Tissues were permeabilized and underwent an internal control contraction. After
full relaxation, each tissue was incubated in a specific enzyme inhibitor for 15 minutes,
except for the myristolated PKC peptide inhibitors, which were preloaded for one hour.
Control tissues received either no inhibitor or the vehicle used to dissolve the inhibitor.
Tissues were immersed in pCa 6.25 solution to generate a sub-maximal contraction.
Once steady-state was reached in pCa 6.25 solution, contractions were potentiated with 1
µM phenylephrine (PE) to promote α-adrenergic receptor-induced Ca2+-sensitization.
After 10 minutes of sensitized contraction, myograph baths were repeatedly flushed with
RS to relax tissue.
In experiments to explore percent relaxation of PE sensitization, tissues were
allowed to fully relax for 15 minutes subsequent to internal control contraction, without
preloading of kinase inhibitors. Sub-maximal contraction was accomplished with pCa
6.25 and Ca2+ sensitization with 1 µM PE. Five minutes after potentiation with PE,
inhibitors were administered to experimental tissues. Data were recorded until steady-
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Figure 7. – Permeabilization, internal control contraction and PE sensitization. Tissue undergoes
permeabilization in 100 μM β-escin in relaxing solution (RS) at two temperatures. The tissues are
then submerged in RS containing the ionophore A23187 prior to contraction with pCa 6.0
contracting solution that generates an internal control. Tissues are relaxed for 15’ in RS + A23187
containing the experimental inhibitor treatment. A submaximal contraction is elicited with pCa
6.25 solution and which is then titrated with 1 μM PE for force potentiation. Finally, tissues are
washed with RS + A23187 to abolish contraction.

state was reached, approximately 10 minutes after drug introduction. Tissues were then
washed with calcium-free RS to initiate relaxation.
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2.6 PE Sensitization Experiment – Intact Tissue
To determine effects of β-escin permeabilization on Ca2+-induced contraction and
PE-induced sensitization, intact tissues were subjected to a similar protocol for
comparison. Intact artery rings experienced the same regimen of solution changes and
temperature treatments as permeabilized tissues though the intact tissues were immersed
in NPSS through the duration. A sub-maximal contraction comparable to pCa 6.25 in
skinned tissue was achieved at pCa 3.7 as identified on a previously generated Ca2+-dose
response curve for intact tissue (unpublished data from Ratz laboratory). Corresponding
to the time of pCa 6.25 treatment, intact tissues were titrated with 1 μM of 1M CaCl2 and
120 μM of 2.5 M KCl, to depolarize the membrane and contract the artery. After steadystate had been reached, tissues were stimulated with 1 µM PE for 10 minutes at which
point they were washed with NPSS to induce relaxation.

2.7 MYPT1 and MLC Phosphorylation
One-dimensional Western Blotting was performed as previously described (Porter
et al. 2006) to measure the degree of MYPT1-p at Thr-853 and Thr-696 as well as MLCp at Ser-19. Arteries were quick-frozen in 20oC acetone/dry ice slurry at multiple time
points – basal, pCa 6.25 steady state, PE sensitized – then slowly warmed to room
temperature in acetone containing 4% trichloroacetic acid. Tissues were washed in cold
acetone to remove trichloroacetic acid, dried, weighed and homogenized in a buffer
containing 8 M urea, 2% Triton X-100, and 20 mM dithiothreitol. Homogenized samples
were heated to 100oC for 10 minutes, clarified by centrifugation and assayed for protein
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concentrations. Proteins were separated by molecular weight via Tris/Gly SDS-PAGE
and transferred (110V, 4oC, 1hr) onto Immobulin poly(vinylidene diflouride) (PVDF)
membranes (Millipore Co.; Bedford, MA). Membranes were soaked in 3% milk TTBS
solution, containing 0.1% Tween 20, to block non-specific antibody binding sites and
then treated with primary antibody at 4oC overnight.

MYPT1 phosphorylation was

quantified using anti-MYPT1-p853 and anti-MYPT1-p696 antibodies (polyclonal
antibodies produced in rabbit, Millipore Co.; Bedford, MA). Total MYPT1 (monoclonal
antibody produced in mouse, BD Transduction; Franklin Lakes, NJ) was assessed to
ensure loading accuracy. The relative degree of MLC phosphorylation was determined
using a rabbit-derived anti-MLC-pSer-19 polyclonal antibody and a mouse-derived antiMLC monoclonal antibody (Sigma; St. Louis, MO). After washing with deionized H2O
and TTBS, secondary antibody (goat-anti-mouse or goat-anti-rabbit, as needed) with
horseradish peroxidase-conjugated IgG (Sigma; St. Louis, MO) was added in targetspecific dilutions [MYPT1-pThr-853 1:4,000; MYPT1-pThr-696 1:5,000; MYPT1 Total
1:5,000; MLC-p 1:10,000; MLC Total 1:10,000] for 1 hour. Membranes were washed
three times with TTBS for five minutes each, after which protein blots were visualized by
enhanced chemiluminescence (ECL, GE Healthcare; Buckinghamshire, UK). To account
for gel-to-gel variability of ECL intensity, a standard control channel was included in
each gel and band intensities from experimental lanes were reported as fold-control.
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2.8 Drugs and Solutions
H-1152, Y-27632, GF109203X, KN92, KN93, and cell-permeable (myristolated)
pseudosubstrate peptide inhibitors of PKCζ and PKCα/β were from EMD Biosciences
(formerly Calbiochem), San Diego, CA. β-escin and phenylephrine were from Sigma
Corporation, St. Louis, MO. Wortmannin was from Alexis Biochemicals, San Diego, CA.
Staurosporine was from Cayman Chemical (Ann Arbor, MI) and A23187 was provided
by Fisher Scientific, Pittsburg, PA.
GF109203X,

wortmannin,

staurosporine

and

A23187

were

dissolved

in

dimethylsulfoxide (DMSO), while all other compounds were dissolved in deionized
water. Permeabilizing solution was generated by dissolving solid β-escin in relaxing
solution. Vehicles (DMSO and ethanol) were added at final concentrations no more than
0.1%, which had no effect on KCl-induced contractions.

2.9 Statistics
The n value for each experiment comprised the number of rabbits from which
arteries were harvested. Raw data were recorded, normalized and entered into GraphPad
Prism 5.0 (GraphPad Software, Inc., San Diego, CA).

The null hypotheses were

examined using a one-way analysis of variance (ANOVA) and were rejected at p<0.05.
Differences between experimental groups were analyzed using the Neuman-Keuls posthoc test. Alternatively, the student’s unpaired t-test was used to determine whether
normalized data were different than unity (one) and the null hypothesis was rejected at
p<0.05. In PE sensitization experiments, normalized steady-state tension was used to
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observe deviations in pCa 6.25 contractions.

Because PE treatment did not create

identical force profiles, total area under the force curve was employed to analyze
differences between PE contractions. The areas of the force versus time curve above the
pCa 6.25 steady-state were compared by ANOVA to identify differences in PE
potentiation.

Calcium dose response curves were assembled using the Prism “Log

agonist-response” equation: Y=Minimum + (Maximum – Minimum)/(1+10^((LogEC50 –
X)*Hillslope)), where X was the pCa value and Y was the force, to generate sigmoidal
pCa-force curves. Statistics were examined for the four defining parameters: Maximum,
Minimum, LogEC50, and Hillslope. Graphical representations were based on curve-fit
data incorporating the average of these four parameters across all empirical curves.
Statistical analyses and curve fitting were performed using Prism 5.0 and SigmaPlot 9.01
(Systat Software, Inc., San Jose, CA).
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RESULTS
3.1 Calcium Concentration Response Curves (CRCs)
The pCa-force curves for β-escin skinned tissues complemented the curves for
other permeabilizing agents previously developed in the Ratz lab (Clelland, 2007). To
specifically examine the involvement of particular kinases in Ca2+-only contraction, it
was necessary to compile Ca2+ CRCs for a range of protein inhibitors.

Tissues in

calcium-free relaxing solution were preloaded with the kinase inhibitors for a period of
15 minutes. Kinase inhibitors were also added to all of the contracting solutions utilized
to construct the CRCs.

Figure 8A-E displays the curves generated for 1 μM

staurosporine (non-specific Ser/Thr kinase inhibitor), 1 μM wortmannin (MLCK
inhibitor), 3 μM H-1152 and 10 μM Y-27632 (ROCK inhibitors) and 1 μM GF109203X
(conventional and novel PKC inhibitor). Maximum and minimum tension, LogEC50 and
Hill Slope [Table 1 and Table 2] values were compared to control values to assess
differences between resultant curves.
The necessity of a kinase cascade for smooth muscle contraction was reconfirmed
when 1 µM staurosporine completely abolished contraction through all Ca2+ doses (N=3).
The staurosporine curve had a negative Hill Slope, correlating increasing Ca2+
concentration to a small decrease in force. The expected inhibition of MLCK with 1 µM
wortmannin produced a depression in maximum force development [p<0.0001, N=3] and
shifted the curve to the right, displaying higher LogEC50 [p<0.05]. The minimum force
and Hill Slope of the wortmannin curve coincided with values from the control CRC.
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Figure 8. – Calcium concentration response curves (CRCs). (A) 1 µM Staurosporine, (B) 1 µM
Wortmannin, (C) 3 µM H-1152, (D) 10 µM Y-27632 and (E) 1 µM GF109203X with CRCs for
corresponding control tissues represented as dashed lines.
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When permeabilized tissue was treated with 1 µM GF109203X, the maximum
force was reduced to 20% of the maximum in the control curve showed [p<0.0001, N=4].
The minimum force value, LogEC50 and Hill Slope all coincided with the control curve
when PKC activity had been blocked.

Ca2+-dose response curves for the ROCK

inhibitors, H-1152 (3 µM, N=8) and Y-27632 (10 µM, N=5), did not differ from the
minimum force of the control curve, but they exhibited a decrease in maximum force
[p<0.0001 for both]. Inhibition of ROCK did not alter the LogEC50 or the Hill Slope of
the generated curves for H-1152 or Y-27632.
Staurosporine [N=3]

Wortmannin [N=3]

C

E

C

E

MIN

0.00

-0.28±0.02∗

0.00

0.00

MAX

1.07±0.14

-0.02±0.19∗

1.38±0.23

0.86±0.13∗

EC50

5.94±0.05

6.20±0.48

6.20±0.02

5.80±0.08∗

Hill

3.70±0.17

-20.3±9.6∗

4.28±0.17

2.87±0.45

Table 1. – CRC parameters for Staurosporine [1 μM] and Wortmannin [1 μM]. Values for
minimum (MIN) and maximum (MAX) force, LogEC50 (EC50) and HillSlope (Hill) for the
CRCs of the control (C) and experimental (E) treatments along with standard error values. [* =
p>0.05 relative to the corresponding control value]

H-1152 [N=8]

Y-27632 [N=5]

GF109203X [N=4]

C

E

C

E

C

E

MIN

0.00

0.00

0.00

0.00

0.00

0.00

MAX

1.13±0.12

0.84±0.08∗

1.14±0.20

0.69±0.08∗

0.69±0.08

0.19±0.07∗

EC50

5.96±0.09

6.00±0.07

6.14±0.12

6.09±0.12

5.56±0.05

5.45±0.09

Hill

3.70±0.26

4.50±0.28

3.52±0.60

4.05±0.72

3.46±0.47

16.1±12.5

Table 2. – CRC parameters for H-1152 [3 μM], Y-27632 [10 μM] and GF109203X [1 μM].
Values for minimum (MIN) and maximum (MAX) force, LogEC50 (EC50) and HillSlope (Hill)
for the CRCs of the control (C) and experimental (E) treatments along with standard error values.
[* = p>0.05 relative to the corresponding control value]
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3.2 Intact versus Permeabilized Femoral Artery
To determine whether Ca2+ sensitization was physiologically viable in skinned
tissues, arterial rings were contracted with pCa 6.25 solution and sensitized with the αadrenergic receptor agonist, phenylephrine (PE, 1 μM) in the absence (control) and
presence of 3 μM H-1152 [Fig 9A]. For a comparison, intact tissues were treated
similarly, using 0.2 mM CaCl2 (pCa 3.7) in a depolarizing solution (110 mM KCl added
to RS) that produced F equivalent to that produced by pCa 6.25 in permeabilized tissue.
Figure 9 displays typical tracings of normalized force for intact tissue [Fig 9A]
and β-escin permeabilized tissue [Fig 9B] treated with pCa 3.7 and pCa 6.25,
respectively, followed by 1µM PE.

Force values were normalized to the control

contraction produced. Upon treatment with 1 µM PE, intact and permeabilized control
tissues showed marked increase in tension above that induced by stimulation with a submaximal Ca2+ concentration. When pretreated with 3 μM H-1152, the maximum PEinduced force was abrogated in both intact (90%±1% inhibition) and skinned (63%±8)
rabbit femoral artery [Fig 1C], confirming that ROCK played a substantial role in Ca 2+
sensitization after permeabilization.

Importantly, 3 μM H-1152 also significantly

inhibited steady-state tension developed upon stimulation of intact muscles with pCa 3.7
(50%±8%) and skinned muscles with pCa 6.25 (30%±7%) [Fig 1D]. The decrease in
Ca2+-generated force by the ROCK inhibitor indicated that Ca2+ sensitization could occur
as the result of direct activation of ROCK by [Ca2+]i. This experiment confirmed that
cellular signaling mechanisms responsible for Ca2+ sensitization could survive β-escin
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cellular permeabilization, allowing examination of Ca2+-induced Ca2+ sensitization in a
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Figure 9. – Intact vs. permeabilized artery treated with 3 µM H-1152. (A) Force tracing for intact
tissue, (B) force tracing for tissue permeabilized with 100 µM β-escin, (C) contractile force when
contracted with Ca2+ solution relative to control, and (D) contractile force when potentiated with
1 µM PE relative to control [N=3, *=p<0.05]
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3.3 ROCK Inhibition of PE Sensitization
To elucidate the involvement of ROCK in Ca2+- and PE-induced contractions,
further experiments using the above protocol examined the correlation between force
development and MYPT1 and MLC phosphorylation levels.

Figure 10 displays a

representative force tracing for two skinned femoral arteries, one acted as a control while
the other was pretreated with 3 µM H-1152 [Fig 10A]. The specific ROCK inhibitor Y27632 was used to confirm the data obtained with H-1152. Ca2+-induced force was
significantly below the control in tissue rings pretreated with 3 µM H-1152 (24%±6%)
and 10 µM Y-27632 (32%±14%) [Fig 10B]. Pretreatment with 3 µM H-1152 and 10 µM
Y-27632 also prevented a significant increase in force due to α-adrenergic Ca2+
sensitization initiated with 1 µM PE (44%±15% [N=5, p>0.05] and 80%±3% [N=4,
p>0.0001] respectively).
One-dimensional Western blot analysis was undertaken to compare the relative
phosphorylation levels of MYPT1 and MLC in a tissue pretreated with 3 µM H-1152
versus control. Tissues were frozen at the plateau of a pCa 6.25 contraction as well as
two minutes after administration of 1 µM PE. Addition of 1 µM PE produced qualitative
increases

in

MYPT1

phosphorylation

at

Thr-853

(34%±37%)

and

Thr-696

(560%±332%), as well as MLC phosphorylation at Ser-19 – all indicators of sensitized
contractile force. 3 µM H-1152 eliminated MYPT1 phosphorylation at Thr-853 during
both Ca2+ contraction and PE-sensitization [Fig 10C], but there was no change in
MYPT1-pThr-696 or total MYPT1 [data not shown].

Western Blots for MLC
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phosphorylation indicated that 3 µM H-1152 prevented an increase in MLC-p Ser-19 [Fig

B.
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Figure 10. – Inhibition of PE-induced sensitization by pretreatment with ROCK inhibitors. (A)
Typical force tracing for inhibition of pCa 6.25 and PE-direct contraction by 3 µM H-1152, (B)
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3.4 Additional Kinases in PE Sensitization
After observing that H-1152 was comparably effective in skinned and intact
tissues for inhibition of both calcium-induced and PE-induced contraction, the same
protocol was used to examine the effect of inhibiting other kinases included in traditional
Ca2+ sensitization models.

The targets of inhibition were protein kinase C (PKC),

Calmodulin-dependent kinase (CaMKII) and MLCK; additionally a general Ser/Thr
kinase inhibitor, 1 μm staurosporine, was also used to inhibit ILK but not ZIP kinase.
The general PKC inhibitor, GF109203X, and peptide pseudo-substrate inhibitors
for PKCα/β and PKCζ/λ isoforms were utilized to explore the behavior of PKC in Ca2+induced Ca2+-sensitization. During pCa 6.25 contraction, arterial rings pretreated with 1
µM GF109203X and 10 µM PKCα/β peptide inhibitor displayed significant reduction of
force (25%±10% and 36%±11% inhibition respectively) [Fig 11A], though there was no
force reduction due to incubation of tissues in 10 µM PKCζ/λ peptide inhibitor.
Interestingly, none of the PKC inhibitors at the aforementioned concentrations obstructed
PE-directed Ca2+ sensitization [data not shown].

CaMKII was documented to be

activated by Ca2+ upstream of ROCK, and could participate in ROCK activation
(Sakurada et al. 2003). However, KN-93, a CaMKII inhibitor, did not inhibit Ca2+induced contraction [Fig 11B]. Inhibition of MLCK with 1 µM wortmannin reduced
force development in pCa 6.25 solution by 76%±1% [Fig 11C] and also suppressed the
PE Ca2+ sensitization effect by 69%±7% [Fig 11D]. Staurosporine at 1 µM inhibits
MLCK, ROCK, PKC, ILK and others, but the drug must be present at 10 µM to inhibit
ZIP kinase (Niiro and Ikebe 2001). Since 1 µM staurosporine fully eliminated force
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development the data suggest that ZIP kinase played no role in Ca 2+-induced or PEinduced force development.
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the Ca2+ sensitization pathway. (A) pCa 6.25-induced force during PKC inhibition with
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3.5 Percent Relaxation
Exposing tissues to protein kinase inhibitors subsequent to onset of α-adrenergic
Ca2+ sensitization facilitated identification of kinases that were actively involved in PEinduced force maintenance. Drugs were introduced after stimulation with 1 µM PE for
five minutes, the approximate time to reach maximum force and MLC phosphorylation
(Somlyo 1997). The control tissue exhibited a small amount of relaxation (12%±3%)
over the five minute contraction, as documented in the force tracing in Fig 12A. The
effect of experimental drug treatments reported as a % relaxation can be seen in Fig 12B.
Kinase inhibitors that abrogated PE-induced Ca2+ sensitization through pretreatment also
caused relaxation far beyond the control tissue: 3 µM H-1152 [Force tracing Fig 12A]
(45.1%±1.3%, p<0.0001, N=3), 10 µM Y-27632 (28.9%±3.4%, p<0.05, N=6), 1 µM
wortmannin (47.8%±11.0%, p<0.0001 N=3), and 1 µM staurosporine (65.0%±9.5%,
N=3). Neither 1 µM GF109203X (10.4%±15%, N=3) nor 5 µL DMSO vehicle (12.1%±
3.8%, N=3) deviated from the relaxation observed in the control, which corroborated the
absence of inhibition when administered prior to PE-directed Ca2+-sensitization.
3.6 Basal MYPT1-p and MLC-p
KCl-induced Ca2+ sensitization may be the result of Ca2+ directly activating the
ROCK sensitization pathway, or alternately, constitutive ROCK activation could provide
basal Ca2+ sensitization. To examine basal activity, skinned tissues were incubated in RS
with kinase inhibitors, frozen and then analyzed via 1-D Western Blot. Decreases in
MYPT1 and MLC phosphorylation would indicate that the inhibited kinase was
constitutively active and contributed to basal Ca2+-sensitization. Inhibition of ROCK
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using 3 µM H-1152 decreased MYPT1-pThr-853 [Fig 13A, p<0.0001, N=9] and MLC-p
Ser-19 [Fig 13B, p<0.0001, N=9], though there was no significant change in MYPT1pThr-696 (data not shown). These results were reinforced by experiments with 10 µM Y27632, which also decreased MYPT1-pThr-853 [p<0.001, N=4] and MLC-p [p<0.0001,
N=4] and similarly showed no significant alteration of MYPT1 Thr-696 phosphorylation.
Interestingly, H-1152 administered at 1 µM significantly reduced MYPT1-pThr-853
[p<0.001, N=3], but although the average MLC-p value was less than the control value
this reduction was not statistically significant [p=0.24, N=3]. Inhibition of PKC using 1
µM GF109203X produced a non-significant increase of the average MYPT1-pThr-853
value, and was coupled with a decrease in MLC-p [p<0.05, N=3].
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DISCUSSION
Results from the present study support the hypothesis that ROCK participates in
KCl-induced Ca2+ sensitization. Chemically permeabilized (“skinned”) rabbit femoral
arteries treated with ROCK inhibitors H-1152 or Y-27632 showed decreased pCa 6.25induced and α-adrenergic GPCR-induced contraction compared to tissues not treated with
ROCK inhibitors (control). Moreover, the maximum force produced during a Ca 2+
concentration response curve (CRC) was also reduced by ROCK inhibition. H-1152
significantly decreased phosphorylation of the MLCP regulatory site MYPT1-pThr-853
during sub-maximal Ca2+-induced contraction and PE-induced force potentiation.
Importantly, skinned tissues treated with ROCK inhibitors in a calcium-free solution
showed decreased MYPT1-pThr-853 and MLC-p, suggesting that ROCK was
constitutively active, and was responsible, at least in part, for basal MLC-p in
unstimulated muscle. Incorporation of constitutive ROCK activity into the current model
of smooth muscle contraction would account for the observation of Ca2+ sensitization by
KCl contraction without necessitating activation of ROCK via depolarization or Ca2+
influx. The description of Ca2+ sensitization as a leftward shift in the pCa-force curve
remains a valid assertion, but our data suggests that the current model of Ca2+
sensitization may need to be adjusted to account for the effect of basal regulation of
MYPT1 and MLC phosphorylation by kinases such as ROCK.
The presence of constitutive ROCK activity does not negate the possibility of
additional sensitization due to depolarization or indirect Ca2+ activation of sensitizing
pathways. Chemical permeabilization of femoral arteries facilitated the investigation of
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the KCl-directed sensitizing stimulus by abrogating resting cell membrane polarization,
effectively eliminating one of two possible stimuli (depolarization and/or increases in
[Ca2+]i), and allowed us to directly test the hypothesis that Ca2+ can activate ROCK
leading to Ca2+ sensitization. Permeabilization was performed with the technique of
Kitazawa (1989), but multiple protocols were tested to identify the appropriate
temperature and time period for permeabilization for New Zealand White rabbit femoral
artery. Permeabilization trials included experimentation with 1 μM wortmannin that
demonstrated that MLCK inhibition markedly attenuated force, indicating minimal loss
of calmodulin over the experimental duration thus obviating the need to reintroduce the
enzyme into the experimental milieu.
The attenuation of force by ROCK inhibitors could result from one of two
possible mechanisms: reduction of the basal level of MLC-p prior to activation of MLCK
or by inhibition of the amount of MLC-p increase during muscle activation (Figure 14).
Our data demonstrate a significant decrease of basal MLC-p by ROCK inhibitors and
therefore support the inhibitory model seen in Figure 14C A recent study by Rembold et
al. indicates that 15% of cellular MLC must be phosphorylated before appreciable levels
of active force can be generated (Rembold et al. 2004). No basal inhibition of force was
observed in tissues treated with ROCK inhibitors despite significant reduction in
MYPT1-pThr853 and MLC-p. Therefore the inhibition of basal MLC phosphorylation
may represent a newly described regulatory mechanism that would be expected to control
the degree of force induced by any contractile stimulus.
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Figure 14. – Mechanism of MLCp inhibition. Reduction of MLCp could occur through one of
two possible mechanisms to achieve the same final degree of phosphorylation and force
development. (A) The cycle of phosphorylation of MLC [k1 = MLCK rate constant; k2 = MLCP
rate constant], (B) the basal phosphorylation is constant and the extent of increase upon
stimulation is lessened or (C) the baseline phosphorylation is decreased and the degree of increase
due to stimulation is unchanged. The true mechanism is likely a combination of these two
disparate ideas.

Staurosporine (1 μM) administration produced a CRC with a negative Hill Slope,
representing a small decrease in force with increasing Ca2+ concentration. The decrease
in force with increasing [Ca2+] was likely due to visco-elastic relaxation over the
extended time course or activation of calcium-dependent proteases at high [Ca2+]i.
Alternatively, the data suggest that another kinase, possibly ILK, may adjust passive
force. Passive force is adjustable in bladder smooth muscle (Speich, et al. 2007), but
whether that is also true for vascular smooth muscle (VSM) remains to be determined.
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The absence of any force development in the presence of staurosporine supports the
model of smooth muscle contraction that requires Ser/Thr phosphorylation. The CRC
produced in the presence of wortmannin displayed significant inhibition of force,
reinforcing a predominant role for MLCK in permeabilized VSM. However, there was
considerable force development (60% fold-control) produced at the highest pCa value
used during the CRC in the presence of 1 μM wortmannin though this concentration of
inhibitor is reported to achieve 90% inhibition of MLCK (Davies, Reddy et al. 2000).
The presence of considerable contraction despite the potent inhibition of MLCK infers
the possibility of MLCK-independent phosphorylation of MLC leading to force
development, for which function ROCK has been identified (Amano et al. 2002).
Because staurosporine abolished the ability of Ca2+ to cause contraction but ROCK, PKC
and MLCK inhibition did not, these data suggest that another kinase may also play a role
in regulation of Ca2+-dependent MLC-p. Of the two most likely candidate kinases, our
data support the hypothesis that ILK rather than ZIP kinase played in a role in rabbit
femoral artery because 1μM staurosporine inhibits ILK but not ZIP kinase (Niiro and
Ikebe 2001).
The ROCK inhibitors, H-1152 and Y-27632, produced similar CRCs with
decreased maximum force relative to control tissues, indicating participation of ROCK in
Ca2+-induced contraction. PKC also played a substantial role in Ca 2+-induced contraction,
as seen by the ~70% inhibition compared to control when tissues were treated with 1 μM
GF109203X. These results correlate to traditional models of Ca2+ sensitization mediated
by PKC and ROCK separately, but also support recent findings that PKC activates the
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RhoA/ROCK pathway (Sivasankaran et al. 2004, Baek, Jeon et al. 2008). The presence
of PKC as an upstream activator of ROCK would account for the considerably larger
inhibition by GF109203X compared with the ROCK inhibitors. Therefore, PKC may
have caused sensitization via CPI-17 inhibition of MLCP as well as activation of ROCK
to phosphorylate MYPT1-pThr853, potentiating the inhibition. Western blots for tissues
at rest in calcium-free solution demonstrate that GF109203X treatment reduced MYPT1pThr-853 phosphorylation as well as MLC-p to a degree comparable to ROCK inhibitors,
although MYPT1 is not a preferred PKC substrate.
Comparison between intact and β-escin permeabilized femoral arteries was
completed to ensure physiological relevance of the permeabilization technique. Results
showed equivalent levels of contraction using pCa 3.7 in the presence of depolarizing
solution for intact tissues and a pCa 6.25 solution in skinned tissues, as well as equivalent
further contraction induced by addition of 1 µM PE at steady state of the contraction
induced by Ca2+. In intact and skinned tissues, inhibition of ROCK with 3 µM H-1152
significantly decreased tension during Ca2+- and PE-induced contractions. Due to the
similar results in intact and skinned muscles, the β-escin treatment regimen can be
concluded to generate viable permeabilized cells while maintaining the biochemical
signaling pathways involved not only in PE-induced, but also Ca2+-induced, ROCKdependent Ca2+ sensitization.

In short, these data support the hypothesis that KCl-

induced Ca2+ sensitization can be attributed to Ca2+-induced Ca2+ sensitization and/or
constitutive ROCK activity. Western blot analysis of MYPT1 and MLC phosphorylation
showed that during pCa 6.25 contraction, MYPT1-pThr-853 was reduced 10-fold by 3
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μM H-1152 relative to the control tissue, but drug treatment had no effect on MYPT1pThr-696 or MLC-p Ser-19. The absence of a detectable decrease in MLC-p concomitant
to decreased MYPT1-pThr-853 could be because sub-maximal Ca2+ stimulation promotes
a minimal change in MLC-p beyond the resolution of our measurements. The PEdirected phosphorylation of MYPT1 and MLC was abolished by 3 μM H-1152 treatment
and tissues displayed phosphorylation levels comparable to the control value measured
prior to PE administration. This suggests that ROCK acts as the primary kinase in the αadrenergic receptor-induced Ca2+ sensitization pathways of permeabilized VSM.
The incubation of salient kinase inhibitors during pCa 6.25 contraction followed
by PE administration identified enzymes involved in GPCR and/or Ca2+-specific
contraction. PE-directed induction of sensitization was significantly inhibited by both
ROCK inhibitors (H-1152 and Y-27632) as well as by wortmannin and staurosporine, but
none of the PKC inhibitors caused a decrease in α-adrenergic receptor-stimulated force.
Relaxation induced at the peak of PE-potentiated force further signifies integral
involvement of an enzyme in sensitized force potentiation. Corroborating the results seen
when tissues were preloaded with a kinase inhibitors, tissues significantly relaxed when
inhibitors of ROCK and MLCK were added at the peak of the PE-induced contraction in
tissues pre-contracted with Ca2+ at pCa 6.25. This was also true when the general Ser/Thr
inhibitor staurosporine was used. The conventional/novel PKC inhibitor, GF109203X,
did not cause relaxation (i.e., the response in the presence of GF109203X was identical to
the time-dependent control response). These results confirm that ROCK and MLCK
appear to be integral components of the α-adrenergic receptor-induced Ca2+ sensitization
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pathway. However, the data suggest that no PKC isotypes (conventional/novel/atypical)
are activated by PE, at least under these conditions in which tissues were first contracted
with Ca2+ at pCa 6.25, then stimulated with a submaximum PE concentration. This is
contrary to previous studies indicating atypical PKC (PKCζ) activation by high doses
(100 μM) of PE (Somlyo 1997).

Predominance of ROCK and absence of PKC

involvement in PE-directed sensitization indicates that α-adrenergic receptor-induced
Ca2+ sensitization is accomplished primarily through MYPT1 phosphorylation rather than
CPI-17 activation.

Furthermore, this evidence suggests that the potential interaction

between the RhoA/ROCK and PKC pathways is unidirectional for PKC activation of
ROCK since there was no force inhibition by GF109203X when ROCK was certainly
activated. The hypothesized activation of ROCK by PKC yields a new model of Ca2+
sensitization of VSM (Figure 15).
A comparison between the pCa 6.25 and PE-treated portions of the force tracing
elucidated involvement of distinct kinases in two distinct phases of force production.
Several kinases participated in the GPCR-activated force development as well as the
Ca2+-only component of contraction. Ca2+ clamped contraction (at pCa 6.25) was reduced
by H-1152, Y-27632, wortmannin, staurosporine, GF109203X and the PKCα/β
pseudosubstrate inhibitor.

These results support the hypothesis that ROCK and

conventional and/or novel PKC along with MLCK and other Ser/Thr kinases participate
in Ca2+-induced contraction.

At 1μM, GF109203X inhibits conventional and novel

PKCs, but not atypical PKCζ/λ isotypes (Martiny-Baron, Kazanitez et al. 1993). When a
specific PKCζ/λ pseudosubstrate inhibitor was administered during the PE sensitization
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protocol there was no significant deviation from control at pCa 6.25 or during PEinduced force potentiation. These data coincide with the hypothesis that PKCζ/λ is
responsible for regulation of Ca2+ levels that can modulate force maintenance (Ratz and
Miner 2008). Permeabilization would have disrupted any forms of Ca2+ regulation and
thus obviated any effect by PKCζ/λ inhibition.
Constitutive ROCK activity and the consequent basal Ca2+ sensitization would
prime the muscle for rapid contraction upon activation, but also allow for sensitizing or
desensitizing modulation to account for variable physiological demands.

Though a

transient increase in [Ca2+]i does not upregulate recruitment and activation of cytosolic
RhoA-GDI to the plasma membrane, a substantial amount of cellular RhoA (18%) is
basally localized to caveolae in rabbit femoral artery (Urban et al. 2003). With the
considerable quantity of active (GTP-bound) RhoA at the membrane, it is possible that
sufficient ROCK will be stimulated to generate modest, but significant basal Ca2+
sensitization. Caveolin-1 knockout and cholesterol depleted tissues that would eliminate
caveolae-based Ca2+ sensitization show no reduction of force in KCl contraction.
However, such experimental set-ups contain inherent disruption of the cellular signaling
apparatus, which includes regulation of membrane potential and Ca 2+ signaling (Darby,
Kwan and Daniel 2000; Babiychuk, Smith et al. 2004), and cannot conclusively preclude
caveolae as a possible regulatory site for sensitization. Contrary to published work, our
laboratory has produced data indicating that caveolar disruption does inhibit a KClinduced contraction by ~40%. Additionally ROCK is involved in maintenance of the
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cytoskeleton (reviewed by Riento and Ridley, 2003) and therefore a moderate level of
activation would account for cellular integrity.

4.1 Translational Relevance
The level of intracellular Ca2+ is an important controller of the two force directing
mechanisms in smooth muscle – Ca2+-induced contraction and Ca2+ sensitization.
Calcium is particularly salient in the pathophysiology of vascular resistance vessels since
hypertensive rats are shown to express larger quantities of L-type Ca 2+ channels and their
pore forming α1C subunit that correlates to increased Ca2+ influx upon contraction
stimulation and membrane depolarization.

Chronic hypertension affects 45 million

individuals in the United States, leading to multiple pathologies. Abnormal expression of
L-type VOCCs leading to increased Ca2+ influx and arterial tone is a common observation
in all forms of hypertension (Sonkusare et al. 2006) and because the expression of these
VOCCs is regulated at the more complex gene stage, regulation of smooth muscle
contractility on the side of Ca2+ sensitivity my provide an alternative location for
treatment to relax total peripheral resistance. The presence of constitutive levels of
and/or Ca2+-activated ROCK activity would be expected to facilitate basal sensitization,
elevating blood pressure. Controlling the cellular response to Ca2+ is salient in clinical
application because studies have shown that animals and patients suffering from
hypertension display elevated [Ca2+]i compared with normotensive individuals. Smooth
muscle contractility is strongly correlated to ROCK function and a detailed understanding
of the protein cascade would allow improved treatments for disorders of smooth muscle
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organ systems.

ROCK activity has proven particularly significant in treatments of

hypertension and vasospasm in vasculature. Uehata et al. demonstrated that ROCK
inhibition by Y-27632 substantially relaxes arterial contraction and decreases blood
pressure in hypertensive rats (Uehata et al. 1997), suggesting ROCK inhibition as a
possible therapeutic treatment for hypertension.
ROCK has been shown to be involved in the enhanced vasoconstriction inherent
in hypertension (Mukai, Shimokawa et al. 2001) and coronary artery spasm (Kandabashi,
Shimokawa et al. 2000; Shimokawa 2000). Abrogation of coronary vasospasm was
accomplished by inhibition of MYPT1 phosphorylation (Kandabashi, Shimokawa et al.
2000), the main target of ROCK. A recent study demonstrated that the ROCK inhibitor
fusadil precluded coronary constriction upon acetylcholine challenge (Masumoto et al.
2002), indicating ROCK as a primary mediator of coronary spasm. This identifies a
possible therapeutic target for coronary artery spasm, which is the underlying pathology
in unstable angina, acute myocardial infarction, sudden cardiac death and other ischemic
heart diseases (Mohri M, Shimokawa H, and Taekshita A 2002).
Furthermore, a recent study of common ROCK polymorphisms in human twins
indicated that the common non-synonymous single nucleotide polymorphism (SNP;
Thr431Asn) generated phenotypes of higher resting diastolic blood pressure and systemic
vascular resistance, and altered endogenous renin-angiotensin coupling (Seasholtz et al.
2006). Residue 431 is located in the coiled-coil domain of ROCK, which is thought to
participate in ROCK autoinhibitory dimerization as well as Rho binding and consequent
activation (Loriand, Guérin and Pacaud 2006).

The realization of genetic factors
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directing ROCK activity provides a possible method for early diagnosis of hypertension
based on genetic risk factors.
ROCK involvement has been identified in many vascular and cardiac
mechanisms, including: PGDF-induced VSM cell proliferation, cardiac myocyte
differentiation, vascular re-stenosis, atherosclerosis and pulmonary hypertension
(reviewed by Loriand, 2006). Moreover, ROCK regulates stress fiber formation in nonmuscle cells, contributing to endothelial cell permeability and cellular migration. These
phenomena are significant in angiogenesis, tumor metastasis, wound repair and neurite
retraction in neurons (reviewed by Riento and Ridley, 2003). With a complete model of
ROCK function, modulation of the kinase activity could provide therapeutic benefits for
many disease states.
In conclusion, our data support the hypothesis that there exists a degree of
constitutive ROCK activity that contributes to basal MLC-p and possibly to Ca2+-induced
sensitization, resulting in Ca2+ sensitization independent of activation of femoral artery
GPCRs.

Furthermore, our data support the hypothesis that certain PKC isotypes,

including PKCα/β may be involved in activation of components upstream from ROCK.
Further elucidation of the pathways for activation of ROCK and the substrates that this
enzyme acts upon will prove very significant in the treatment of a myriad of pathologies.

4.2 Further Experiments
-

MYPT1-p and MLC-p Western blots examining the difference between basal and
Ca2+-contracted phosphorylation levels in the presence of ROCK and PKC
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inhibitors. The current series of gels showed increases above Ca2+-activated
levels as a result PE stimulation, but comparison between basal and activated
states would further elucidate the mechanism for force inhibition.
-

Use confocal microscopy to examine the extent of membrane disruption by βescin permeabilization. Extensive damage to caveolae and other membrane
bound-apparatus could activate/deactivate salient protein cascades.

-

Treatment of permeabilized tissues with the BEL compound prior to Ca2+clamping. BEL inhibits phospholipase A2 from producing arachidonic acid,
which is a known activator of ROCK. This experiment determines if decrease of
force with ROCK inhibitors occurs because arachidonic acid is present in the
experimental milieu.

-

Calcium concentration response curves including wortmannin and a ROCK
inhibitor compared to a control and a tissue treated with 1 µM staurosporine.
Contraction in the presence of the MLCK and ROCK inhibitors would indicate
the participation of another kinase in force development.

-

Measure CPI-17 phosphorylation in intact and permeabilized tissue during rest
and stimulation with Ca2+ and/or PE. This will indicate if the main inhibitory
mechanism of PKC is to activate CPI-17 for direct inhibition of MLCP or to
activate the RhoA/ROCK pathway. The experiment will also help elucidate
specific roles for different PKC isotypes.

-

Perform similar array of experiments in mice with ROCK or PKC knockouts.
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